<DOC>
	<DOCNO>NCT00002916</DOCNO>
	<brief_summary>RATIONALE : Vaccines make human papillomavirus may make body build immune response kill cervical cancer cell . Combining vaccine therapy surgery may effective treatment cervical cancer . PURPOSE : This phase II trial study well give vaccine therapy together surgery work treat patient early cervical cancer .</brief_summary>
	<brief_title>Surgery Vaccine Therapy Treating Patients With Early Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate systemic immunological response human papilloma virus vaccine ( TA-HPV ) express protein 16 , 18 , E6 E7 examine cytolytic T cell antibody responses cervical cancer patient . - Investigate safety toxic effect TA-HPV patient . - Assess proliferative capacity T cell E6 E7 proteins . - Observe influence vaccination TA-HPV disease free interval pattern recurrence patient . OUTLINE : This open-label , nonrandomized study . Patients receive 2 vaccination human papilloma virus protein 16 , 18 , E6 E7 least 4 week apart , first vaccination least 2 week surgery second 8 week first one , unless unacceptable toxicity occurs . Patients require radiotherapy follow surgery receive second vaccination 4-8 week first vaccination . Twenty-eight patient enter initially ; least 2 patient show immunologic response , 16 additional patient enter . Patients follow every 3 month 2 year , every 6 month 3 year , annually . PROJECTED ACCRUAL : 44 patient enter 1 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven untreated stage Ib IIa cervical carcinoma , squamous adenocarcinoma suitable surgical excision No CNS metastases Circulating CD4+ lymphocyte count least 400 Proven absence hepatitis B C antibodies Previous exposure vaccinia smallpox vaccination , well previous exposure , allow Reaction 2 antigen Pasteur Merieux CMI test require Ability collaborate plan followup require PATIENT CHARACTERISTICS : Age : 19 Performance status : WHO/ECOG great 2 Life expectancy : At least 3 month Hematopoietic : WBC great 3,000 ( 3,000 x 10 ninth/L ) Platelet count great 120,000 ( 120 x 10 ninth/L ) No bleed disorder Hepatic : Bilirubin le 1.5 time normal AST ALT less 1.5 time normal Prothrombin partial thromboplastin time great 2 time normal Renal : Creatinine le 1.3 mg/dL ( 120 micromoles/L ) Other : No ongoing infection No HIV antibody No serious medical psychiatric illness No second malignancy within 5 year except curatively treat basal cell skin cancer require surgery , hormone therapy , immunotherapy chemotherapy Not pregnant nursing Adequate contraception require Patient household contact must follow : Chronic steroid therapy Renal allograft Known immunodeficiency Eczema Children 5 year old PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>